Mirum Pharmaceuticals (MIRM) Stock Statistics & Valuation Metrics

Mirum Pharmaceuticals has a market cap or net worth of $5.47B. The enterprise value is $4.57B.

Mirum Pharmaceuticals has 60,341,618 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mirum Pharmaceuticals’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -3.46%.

The current PE Ratio of Mirum Pharmaceuticals is ―. Mirum Pharmaceuticals’s PEG ratio is 2.28.

In the last 12 months, Mirum Pharmaceuticals had revenue of 521.31M and earned -23.36M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was 55.83M and capital expenditures -954.00K, giving a free cash flow of 54.87M billion.

Mirum Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Mirum Pharmaceuticals upcoming earnings date is Apr 30, 2026, After Close (Confirmed).

Mirum Pharmaceuticals as a current ratio of 2.67, with Debt / Equity ratio of 101.51%

In the past 12 months, Mirum Pharmaceuticals has paid 1.94M in taxes.

Mirum Pharmaceuticals EV to EBITDA ratio is 231.78, with an EV/FCF ratio of 72.68.

Mirum Pharmaceuticals has $383.33M in cash and marketable securities with $319.45M in debt, giving a net cash position of $63.88M billion.

Gross margin is 80.76%, with operating margin of -4.25%, and net profit margin of -4.48%.

The average price target for Mirum Pharmaceuticals is $121.44, which is 11.43% higher than the current price. The consensus rating is Strong Buy